Merit Medical Systems, Inc. — FY 2014 Form 10-K
Reporting period: Fiscal year ended December 31, 2014. This is an annual filing, not a standalone Q4 filing; Q4 results are also summarized below. Merit designs, manufactures and sells single-use medical devices, principally for cardiovascular and endoscopic procedures.
Financial performance
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Net sales | $509.7 million | $449.0 million |
| Gross profit / margin | $225.2 million / 44.2% | $194.4 million / 43.3% |
| Operating income / margin | $40.2 million / 7.9% | $27.8 million / 6.2% |
| Net income | $23.0 million | $16.6 million |
| Diluted EPS | $0.53 | $0.39 |
| Operating cash flow | $53.3 million | $51.4 million |
| Cash and cash equivalents | $7.4 million | $7.5 million |
| Total debt, including current portion | $224.5 million | $248.9 million |
| Working capital | $116.9 million | $100.3 million |
Q4 2014 sales were $132.8 million, gross profit $60.1 million, operating income $14.2 million and net income $8.7 million; diluted EPS was $0.20. Q4 2013 sales were $120.0 million and net income was $6.5 million.
Changes and operating trends
- FY sales increased 13.5%; international sales rose approximately 20% to $198.3 million, or 39% of total sales. Cardiovascular sales grew 13.8%; endoscopy sales grew 6.3%.
- Gross margin improved from 43.3% to 44.2%, which management attributed mainly to product mix, including BioSphere products, and lower fixed overhead per unit from higher production volumes.
- Net income rose despite higher SG&A, interest expense and the effective tax rate. FY 2014 included a $1.1 million intangible impairment and a $0.6 million contingent-consideration benefit; comparable FY 2013 amounts were an $8.1 million impairment and a $4.1 million benefit.
- Research and development expense was $36.6 million, up 8.1%. Capital expenditures were $34.2 million, down from $59.5 million.
Liquidity, debt and outlook
- Operating cash flow was $53.3 million; investing activities used $36.2 million and financing activities used $17.0 million. Inventory increased by $9.4 million and trade receivables increased by $12.5 million.
- Debt was secured by substantially all company assets. Merit reported $27.5 million of additional borrowing availability under its credit facility and compliance with all covenants at year-end. The credit agreement matures in December 2017; $204.5 million of principal was scheduled for 2017.
- Management expected existing cash, operating cash flows, equipment financing and credit-facility borrowings to fund operations and currently planned needs for the next 12 months and foreseeable future.
- No specific sales or earnings guidance was provided. Management anticipated approximately $45 million of 2015 property and equipment spending. It expected $1.5–$2.5 million of transition-period operating costs in 2015 as the Tijuana facility launches, and planned to shift production there and close the West Jordan manufacturing site. The longer-term aim is to lower costs and improve margins.
Management commentary, risks and contingencies
- Management cited U.S. hospital cost pressure and slight pricing declines in several product markets. Growth was largely driven by unit sales, new products and market-share gains; inflation devices represented approximately 14% of revenue.
- Key risks include medical-device regulation and approval delays, clinical-trial outcomes, product liability or recalls, reimbursement changes, competition and technology shifts, supplier and sterilization concentration, acquisition integration, foreign-exchange exposure, and the ability to generate cash to service debt.
- The 2.3% medical-device excise tax cost $3.5 million in 2014, reducing gross profit by 0.7%. Currency movements increased revenue by approximately $0.5 million; about 19% of sales were denominated in foreign currencies.
- Ostial-related impairment reflected slower-than-anticipated sales growth and uncertainty about future demand. Ordinary-course litigation was disclosed; management did not believe pending matters were likely to be material, while acknowledging an unfavorable outcome could be adverse. Irish grants of approximately $4.4 million could be repayable if production there ceases within the applicable period; management said it had no current intention to cease Irish operations.
- The independent auditor gave an unqualified opinion on the financial statements and internal controls. Management and the auditor concluded internal control over financial reporting was effective as of year-end.
Important facts for investors to verify
- Whether sales growth and gross-margin improvement persist, particularly given pricing pressure and the contribution of BioSphere products.
- Progress, costs and production-transfer risks for the Tijuana launch and West Jordan closure, including whether projected cost savings materialize.
- Debt covenant headroom, scheduled 2017 refinancing or repayment needs, interest-rate exposure and the availability of the stated $27.5 million facility capacity.
- Working-capital and cash conversion trends, especially receivables and inventory growth relative to sales.
- Clinical-trial results and regulatory milestones for the liver cancer, prostate embolization and EndoMAXX EVT indications, alongside the impact of the medical-device tax and reimbursement changes.